Feb 18 2010
The European Medicines
Agency (EMEA) recommends orphan drug status for Aprea's treatment of acute
myeloid leukemia (AML). The treatment is currently undergoing a Phase I
clinical study and a final decision from the European Commission regarding
status is expected in a few weeks. Aprea is part of the Karolinska
Development portfolio.
"Aprea is developing a new class of anticancer drugs for the treatment of
acute myelogenous leukemia, the most common acute leukemia affecting adults
which is currently lacking efficient treatment. An orphan drug status would
significantly shorten the development time, lower development costs and, if
approved, extend market exclusivity to the benefit of affected patients,
Aprea and Karolinska Development," says Conny Bogentoft, CEO Karolinska
Development.
Karolinska Development holds 43 percent of the Aprea share capital and
votes.
SOURCE Karolinska Development AB